Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL554969 | 1.00 | CHRM1 (0.40) | CHRM1CHRM3CHRM2SLC6A2SLC6A3 | |
| SCHEMBL553891 | 1.00 | CHRM1 (0.40) | CHRM1CHRM3CHRM2SLC6A2SLC6A3 | |
| SCHEMBL27602181 | 0.81 | SLC6A2 (0.40) | SLC6A2SLC6A3SLC6A4HRH1 | |
| SCHEMBL31451120 | 0.80 | CHRM1 (0.50) | CHRM1CHRM3CHRM2SLC6A2SLC6A3 | |
| SCHEMBL31264458 | 0.80 | CHRM1 (0.50) | CHRM1CHRM3CHRM2SLC6A2SLC6A3 | |
| SCHEMBL553740 | 0.80 | CHRM1 (0.50) | CHRM1CHRM3CHRM2SLC6A2SLC6A3 | |
| SCHEMBL553741 | 0.80 | CHRM1 (0.50) | CHRM1CHRM3CHRM2SLC6A2SLC6A3 | |
| SCHEMBL553920 | 0.80 | CHRM1 (0.50) | CHRM1CHRM3CHRM2SLC6A2SLC6A3 | |
| SCHEMBL570865 | 0.78 | MGLL (0.42) | — | |
| SCHEMBL16657609 | 0.77 | SLC6A3 (0.52) | SLC6A2SLC6A3SLC6A4NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| EP-2601177-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| CN-103153954-A | N-acylsulfonamide apoptosis promoters | ASTRAZENECA AB | 2013-06-12 | — | — | CN | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | CHRM1 4878/4885CHRM3 4804/4885CHRM2 4830/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | CHRM1 4878/4885CHRM3 4804/4885CHRM2 4830/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | CHRM1 4878/4885CHRM3 4804/4885CHRM2 4830/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | CHRM1 4885/4885CHRM3 4877/4885CHRM2 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.